Neurocrine Biosciences | NBIX - Sales Revenues

Stock Price
131.67
Daily Change
0.44 0.34%
Monthly
-0.05%
Yearly
23.53%
Q2 Forecast
124.95

Neurocrine Biosciences reported $805.5M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
ALKERMES USD 384.5M 9.7M Dec/2025
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Exelixis USD 598.66M 860K Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Prothena USD 21K 2.4M Dec/2025
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Repligen USD 197.91M 8.91M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xoma USD 25K 5M Sep/2024